Benzinga · Aug 5, 2026
Piper Sandler Reiterates Overweight on OrthoPediatrics, Raises Price Target to $25
Piper Sandler analyst Matt O'Brien reiterates OrthoPediatrics (NASDAQ:KIDS) with a Overweight and raises the price target from $22 to $25.
KI
NASDAQ · KIDS
OrthoPediatrics Corp.
Healthcare · Medical - Devices
$25.01
Up+$0.15 (+0.60%)
Updated Aug 14, 2026, 8:13 AM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 459.56M
- P/E ratio
- -9.41
- Dividend yield
- 0.00%
- 52-week range
- $14.42 – $25.01
- Volume
- 205.63K
- Avg. volume
- 199.33K
Price performance
KIDS price history
1M range · 21 trading sessions · Daily adjusted prices
KIDS closed at $25.01 after 21 trading sessions, up 22.72% for the selected period.
- Last close
- $25.01
- Period change
- +22.72%
- Period low
- $18.72
- Period high
- $25.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $25.00 | $25.24 | $24.55 | $25.01 | 205.63K |
| Aug 12, 2026 | $24.33 | $25.01 | $23.995 | $24.86 | 247.54K |
| Aug 11, 2026 | $23.30 | $24.56 | $23.065 | $24.24 | 231.37K |
| Aug 10, 2026 | $22.75 | $23.42 | $22.75 | $23.28 | 258.52K |
| Aug 7, 2026 | $22.78 | $23.17 | $22.477 | $22.77 | 196.26K |
| Aug 6, 2026 | $22.62 | $23.16 | $21.91 | $22.83 | 394.82K |
| Aug 5, 2026 | $22.10 | $22.445 | $20.485 | $22.31 | 709.5K |
| Aug 4, 2026 | $20.90 | $21.17 | $20.70 | $20.88 | 268.89K |
| Aug 3, 2026 | $20.44 | $21.505 | $19.34 | $20.87 | 359.24K |
| Jul 31, 2026 | $20.12 | $20.25 | $19.435 | $20.19 | 114.93K |
| Jul 30, 2026 | $19.84 | $20.39 | $19.75 | $20.11 | 120K |
| Jul 29, 2026 | $19.91 | $20.44 | $19.84 | $19.99 | 185.1K |
| Jul 28, 2026 | $20.04 | $20.49 | $19.70 | $19.84 | 151.74K |
| Jul 27, 2026 | $19.08 | $20.08 | $19.07 | $19.82 | 117.04K |
| Jul 24, 2026 | $18.87 | $19.22 | $18.10 | $18.87 | 141.65K |
| Jul 23, 2026 | $18.98 | $19.16 | $18.38 | $18.72 | 147.89K |
| Jul 22, 2026 | $19.46 | $19.46 | $18.80 | $19.26 | 111.27K |
| Jul 21, 2026 | $19.28 | $20.45 | $18.57 | $19.49 | 166.18K |
| Jul 20, 2026 | $19.26 | $19.74 | $18.90 | $19.52 | 177.33K |
| Jul 17, 2026 | $19.90 | $20.3575 | $19.0605 | $19.215 | 128.15K |
| Jul 16, 2026 | $19.85 | $20.81 | $19.85 | $20.38 | 168.72K |
Latest KIDS news
The latest Smart Investors Daily articles mentioning KIDS.
Stock researchCompany · Overview
KIDS research
Overview
Company profile and research snapshot.
Company profile
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $24.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Needham | Buy | — |
| Aug 5, 2026 | Piper Sandler | Overweight | — |
| Jul 16, 2026 | Truist Securities | Hold | — |
| May 1, 2026 | BTIG | Buy | — |
| Mar 2, 2026 | Truist Securities | Hold | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 5, 2026
Needham Maintains Buy on OrthoPediatrics, Raises Price Target to $35
Needham analyst Mike Matson maintains OrthoPediatrics (NASDAQ:KIDS) with a Buy and raises the price target from $30 to $35.
ChartMill · Aug 5, 2026
OrthoPediatrics (NASDAQ:KIDS) Narrows Q2 Loss, Raises Full-Year Revenue Outlook
OrthoPediatrics (KIDS) Q2 revenue up 15% to $70.5M, adjusted loss beats consensus, and FY guidance raised. Scoliosis dips, Trauma & Deformity leads.
SeekingAlpha · Aug 4, 2026
OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript
OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDTCompany ParticipantsDavid Bailey - President, CEO & DirectorFred Hite -...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
